HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
REZDIFFRA safely and effectively. See full prescribing
information for REZDIFFRA.
REZDIFFRA (resmetirom) tablets, for oral use
Initial U.S. Approval: 2024----------------------------INDICATIONS AND USAGE---------------------------REZDIFFRA is a thyroid hormone receptor-beta (THR-beta) agonist
indicated in conjunction with diet and exercise for the treatment of
adults with noncirrhotic nonalcoholic steatohepatitis (NASH) withmoderate to advanced liver fibrosis (consistent with stages F2 to F3
fibrosis).
This indication is approved under accelerated approval based on
improvement of NASH and fibrosis. Continued approval for thisindication may be contingent upon verification and description ofclinical benefit in confirmatory trials. (1)Limitations of Use
Avoid use of REZDIFFRA in patients with decompensated cirrhosis. (1)----------------------- DOSAGE AND ADMINISTRATION ----------------------• The recommended dosage of REZDIFFRA is based on actual bodyweight. For patients weighing:o <100 kg, the recommended dosage is 80 mg orally once daily.
o ≥100 kg, the recommended dosage is 100 mg orally once daily.
Administer REZDIFFRA with or without food. (2.1)• See full prescribing information for REZDIFFRA dosage
modifications with concomitant use of moderate CYP2C8 inhibitors.
(2.2)--------------------- DOSAGE FORMS AND STRENGTHS --------------------Tablets: 60 mg, 80 mg, and 100 mg (3)-------------------------------CONTRAINDICATIONS------------------------------None.
----------------------- WARNINGS AND PRECAUTIONS-----------------------• Hepatotoxicity: Monitor patients during treatment with REZDIFFRA
for elevations in liver tests and for the development of liver-related

adverse reactions. Discontinue REZDIFFRA and continue to monitor
the patient if hepatotoxicity is suspected. (5.1)• Gallbladder-Related Adverse Reactions: Cholelithiasis andcholecystitis were observed more often in REZDIFFRA-treatedpatients. If cholelithiasis is suspected, gallbladder diagnostic studies
and appropriate clinical follow-up are indicated. If an acutegallbladder event such as acute cholecystitis is suspected, interrupt
REZDIFFRA treatment until the event is resolved. (5.2)------------------------------ ADVERSE REACTIONS -----------------------------The most common adverse reactions with REZDIFFRA (reported in atleast 5% of patients and higher compared to placebo) are: diarrhea,
nausea, pruritus, vomiting, constipation, abdominal pain, anddizziness. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Madrigal
Pharmaceuticals, at 1-800-905-0324 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
-------------------------------DRUG INTERACTIONS------------------------------• Strong or Moderate CYP2C8 Inhibitors: Concomitant use notrecommended (strong inhibitor [e.g., gemfibrozil]); or reduce
REZDIFFRA dosage (moderate inhibitor [e.g., clopidogrel]). (2.2,
7.1)• OATP1B1 and OATP1B3 Inhibitors: Concomitant use with OATP
inhibitors (e.g., cyclosporine) is not recommended. (7.1)• Atorvastatin, Pravastatin, Rosuvastatin and Simvastatin: Limit thedaily dosage of the statin as recommended. (5.3, 7.2)
• CYP2C8 Substrates: Monitor patients more frequently for substraterelated adverse reactions. (7.2)----------------------- USE IN SPECIFIC POPULATIONS ----------------------Hepatic Impairment: Avoid use of REZDIFFRA in patients withmoderate to severe hepatic impairment (Child-Pugh Class B or C).
(8.7)
See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling.
Revised: 03/2024

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage and Administration
2.2 Dosage Modifications for CYP2C8 Inhibitors
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hepatotoxicity
5.2 Gallbladder-Related Adverse Reactions
5.3 Drug Interaction with Certain Statins
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on REZDIFFRA
7.2 Effects of REZDIFFRA on Other Drugs
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy

Reference ID: 5346680

8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION* Sections or subsections omitted from the full prescribing information
are not listed.

FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with
noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent
with stages F2 to F3 fibrosis).
This indication is approved under accelerated approval based on improvement of NASH and fibrosis[see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verificationand description of clinical benefit in confirmatory trials.
Limitations of Use
Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations(8.7), Clinical Pharmacology (12.3)].
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage and Administration
The recommended dosage of REZDIFFRA is based on actual body weight. For patients weighing:••<100 kg, the recommended dosage is 80 mg orally once daily.
≥100 kg, the recommended dosage is 100 mg orally once daily.

Administer REZDIFFRA with or without food [see Clinical Pharmacology (12.3)].
2.2 Dosage Modifications for CYP2C8 Inhibitors
Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is notrecommended [see Drug Interactions (7.1)].
If REZDIFFRA is used concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel) [see Drug
Interactions (7.1)], reduce the dosage of REZDIFFRA:••<100 kg, reduce the dosage of REZDIFFRA to 60 mg once daily.
≥100 kg, reduce the dosage of REZDIFFRA to 80 mg once daily.

3 DOSAGE FORMS AND STRENGTHSREZDIFFRA Tablets:•••

60 mg: white oval-shaped film-coated tablets debossed with “P60” on one side and plain on theother side.
80 mg: yellow, oval-shaped, film-coated tablets debossed with “P80” on one side and plain on theother side.
100 mg: beige to pink, oval-shaped, film-coated tablets debossed with “P100” on one side andplain on the other side.

4 CONTRAINDICATIONS
None.

2

Reference ID: 5346680

5 WARNINGS AND PRECAUTIONS
5.1 Hepatotoxicity
Hepatotoxicity has been observed with use of REZDIFFRA. One patient had normal alanine
aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TB) levels at baseline,
who received REZDIFFRA 80 mg daily, developed substantial elevations of liver biochemistries that
resolved when treatment was interrupted. After reinitiating REZDIFFRA, the patient had elevations of
ALT, AST, and TB. Peak values observed were 58 x upper limit of normal (ULN) for ALT, 66 x ULN
for AST, 15 x ULN for TB, with no elevation of alkaline phosphatase (ALP). Elevations in liver
enzymes were accompanied by elevations in immunoglobulin G levels, suggesting drug-induced
autoimmune-like hepatitis (DI-ALH). The liver tests returned to baseline following hospitalization anddiscontinuation of REZDIFFRA without any therapeutic intervention.
Monitor patients during treatment with REZDIFFRA for elevations in liver tests and for thedevelopment of liver-related adverse reactions. Monitor for symptoms and signs of hepatotoxicity(e.g., fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, fever, rash, and/or
eosinophilia [>5%]). If hepatotoxicity is suspected, discontinue REZDIFFRA and continue to monitor
the patient. If laboratory values return to baseline, weigh the potential risks against the benefits ofrestarting REZDIFFRA. If laboratory values do not return to baseline, consider DI-ALH or autoimmune
liver disease in the evaluation of elevations in liver tests.
5.2 Gallbladder-Related Adverse Reactions
In clinical trials, cholelithiasis, acute cholecystitis, and obstructive pancreatitis (gallstone) wereobserved more often in REZDIFFRA-treated patients than in placebo-treated patients. If cholelithiasis
is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. If anacute gallbladder event is suspected, interrupt REZDIFFRA treatment until the event is resolved [seeAdverse Reactions (6.1)].
5.3 Drug Interaction with Certain Statins
An increase in exposure of atorvastatin, pravastatin, rosuvastatin and simvastatin was observed
when concomitantly administered with REZDIFFRA [see Clinical Pharmacology (12.3)], which may
increase the risk of adverse reactions related to these drugs. Dosage adjustment for certain statins is
recommended [see Drug Interactions (7.2)]. Monitor for statin-related adverse reactions including but
not limited to elevation of liver tests, myopathy, and rhabdomyolysis.
6 ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in labeling:• Hepatotoxicity [see Warnings and Precautions (5.1)]• Gallbladder-Related Adverse Reactions [see Warnings and Precautions (5.2)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of
another drug and may not reflect the rates observed in clinical practice.
The safety of REZDIFFRA was evaluated in two randomized, double-blind, placebo-controlled trials
that enrolled a total of 2019 patients.

3

Reference ID: 5346680

Trial 1
Trial 1 included patients who had noncirrhotic NASH with stages F2 and F3 fibrosis at eligibility(n=888) [see Clinical Studies (14)].
Adverse Reactions Leading to Discontinuations
The exposure-adjusted incidence rates (EAIRs) per 100 person-years (PY) for treatment
discontinuation due to any adverse reaction were higher in the REZDIFFRA dosage arms: 4 per 100
PY, 5 per 100 PY, and 8 per 100 PY in placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100
mg once daily arms, respectively. Diarrhea and nausea were the most common causes of treatment
discontinuation.
Common Adverse Reactions
Table 1 displays EAIRs per 100 PY for the common adverse reactions that occurred in at least 5% of
patients with F2 or F3 fibrosis treated in either drug arm with REZDIFFRA and were greater than thatreported for placebo.
Table 1: Exposure-Adjusted Incidence Rates (EAIR) of Common Adverse Reactions Reportedwith REZDIFFRA in Adult Patients with Noncirrhotic NASH (Trial 1)a, b, cAdverse Reaction

Placebo
N=294
n (EAIRd)

REZDIFFRA 80 mg Once
Daily
N=298
n (EAIRd)

REZDIFFRA 100 mg
Once Daily
N=296n (EAIRd)

Diarrhea

52 (14)78 (23)98 (33)

Nausea36 (9)

65 (18)51 (15)

Pruritus

18 (4)

24 (6)

36 (10)Vomiting

15 (4)

27 (7)

30 (8)

Constipation

18 (4)

20 (5)

28 (8)

Abdominal pain

18 (4)

22 (5)

27 (7)

Dizziness

6 (1)

17 (4)

17 (4)a Population includes adult patients with noncirrhotic NASH with liver fibrosis (stages F2 and F3 at eligibility).

b Median exposure duration was 68 weeks for placebo, 74 weeks for REZDIFFRA 80 mg once daily, and 66 weeks for

REZDIFFRA 100 mg once daily.

c EAIRs are per 100 person-years (PY) where total PYs were 435, 435, and 407 for placebo, 80 mg once daily, and 100

mg once daily arms, respectively.
d The EAIR per 100 PY can be interpreted as an estimated number of first occurrences of the adverse reaction of interest
if 100 patients are treated for one year.
Abbreviations: EAIR, exposure-adjusted incidence rate; PY, person-years; NASH, nonalcoholic steatohepatitis

Gastrointestinal Adverse Reactions
The incidence of gastrointestinal adverse reactions was higher for the REZDIFFRA drug arms
compared to placebo. The EAIRs for gastrointestinal adverse reactions were 57 per 100 PY, 73 per
100 PY, and 89 per 100 PY in the placebo, REZDIFFRA 80 mg once daily, REZDIFFRA 100 mg once
daily arms, respectively.
Diarrhea typically began early in treatment initiation and was mild to moderate in severity. The mediantime (Q1 to Q3) to a diarrheal event was 39 (2 to 195) days, 17 (3 to 70) days, and 6 (2 to 54) days in
the placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100 mg once daily arms, respectively.
4

Reference ID: 5346680

Median duration of diarrhea was 9 days for placebo compared to 20 days for both REZDIFFRA 80 mg
once daily and REZDIFFRA 100 mg once daily dosage arms.
Nausea also began early in treatment and was mild to moderate in severity. Among patients withnausea, the median time (Q1 to Q3) to a nausea event was 85 (24 to 347) days, 28 (2 to 162) days,
and 5 (2 to 40) days in the placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100 mg once
daily arms, respectively. Median duration of nausea was 17 days, 26 days, and 28 days for patients inthe placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA100 mg once daily arms, respectively.
Vomiting and abdominal pain adverse reactions were mild to moderate in severity.
Hypersensitivity Reactions
Reactions such as urticaria and rash, which may reflect drug hypersensitivity, were observed inpatients receiving REZDIFFRA. The EAIRs for urticaria were 0.2 per 100 PY, 0.7 per 100 PY, and 1.5
per 100 PY in the placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100 mg once daily arms,
respectively. The EAIRs for rash were 3 per 100 PY in the placebo and REZDIFFRA 80 mg once
daily arms compared to 5 per 100 PY in the REZDIFFRA 100 mg once daily arm.
Gallbladder-Related Adverse Reactions
A higher incidence of cholelithiasis, acute cholecystitis, and obstructive pancreatitis (gallstone) was
observed in the treatment arms compared to placebo. However, the EAIRs for these events were lessthan 1 per 100 PY for all treatment arms.
Less Common Adverse Reactions
Additional adverse reactions that occurred more frequently in the REZDIFFRA arms compared toplacebo, in less 5% of patients, included decreased appetite, flatulence, abnormal feces, dysgeusia,
vertigo, arrythmia, palpitations, depression, erythema, hypoglycemia, tendinopathy, abnormal uterine
bleeding.
Laboratory Abnormalities
Liver Tests
Increases in mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels
were observed in the first 4 weeks after initiating treatment with REZDIFFRA. In both REZDIFFRA
dosage arms, the mean elevation in ALT and AST values was less than 1.5 times baseline at 4
weeks after treatment initiation. These values returned to baseline around 8 weeks after initiating
treatment.
Table 2 presents the frequency of liver test elevations during Trial 1.
Table 2: Frequency of Liver Test Elevations in Trial 1
Placebo(%)
ALT > 3x ULN
ALT > 5x ULN
AST > 3x ULN
AST > 5x ULN
TBa > 2x ULN

10
2
10
2
2

REZDIFFRA 80 mg
Once Daily
(%)
11
2
9
1
1

a TB elevations include patients with Gilbert syndrome.

Thyroid Function Tests
5

Reference ID: 5346680

REZDIFFRA 100
mg Once Daily
(%)
13
2
12
4
3

A decrease in levels of prohormone free T4 (FT4) of mean 2%, 13%, and 17% was seen at 12
months in patients treated with placebo, REZDIFFRA 80 mg once daily, and REZDIFFRA 100 mg
once daily, respectively, with minimal changes in active hormone T3 or in TSH. There were no clinicalfindings associated with FT4 decreases.
Additional Safety Data
The safety evaluation of REZDIFFRA also included an analysis of an additional randomized placebocontrolled safety trial which included 969 patients from a relevant patient population (placebo [n=318],
REZDIFFRA 80 mg once daily [n=327], and REZDIFFRA 100 mg once daily [n=324]).
Data from the safety trial was combined with data from NASH patients with F2 and F3 fibrosis ateligibility (n=888) and data from an additional 162 patients from a relevant patient population enrolledin Trial 1. In the combined safety population (n=2019), the median (Q1 to Q3) age of patients atbaseline was 58 (50 to 65) years; 55% were female, 28% were Hispanic, 89% were White, 2% were
Asian, and 4% were Black or African American.
The safety profile from this combined analysis was similar to that in Trial 1, other than the one case ofhepatotoxicity in the safety trial [see Warnings and Precautions (5.1)].
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on REZDIFFRA
Table 3 includes clinically significant drug interactions affecting REZDIFFRA.
Table 3: Clinically Significant Interactions Affecting REZDIFFRA
Strong or Moderate CYP2C8 Inhibitors
Resmetirom is a CYP2C8 substrate. Concomitant use with a strong or
moderate CYP2C8 inhibitor can increase resmetirom Cmax and AUC [seeClinical Impact
Clinical Pharmacology (12.3)], which may increase the risk of REZDIFFRA
adverse reactions.
Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g.,
gemfibrozil) is not recommended. Reduce REZDIFFRA dosage if used
Intervention
concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel) [seeDosage and Administration (2.2)].
Organic Anion-Transporting Polypeptides (OATP) 1B1 and OATP1B3 Inhibitors
Resmetirom is an OATP1B1 and OATP1B3 substrate. Concomitant use withOATP1B1 and OATP1B3 inhibitors may increase resmetirom Cmax and AUC
Clinical Impact[see Clinical Pharmacology (12.3)], which may increase the risk of
REZDIFFRA adverse reactions.
Concomitant use of REZDIFFRA with OATP1B1 or OATP1B3 inhibitors
Intervention(e.g., cyclosporine) is not recommended.
7.2 Effects of REZDIFFRA on Other Drugs
Table 4 includes clinically significant drug interactions affecting other drugs.
Table 4: Clinically Significant Interactions Affecting Other Drugs
Statins (Atorvastatin, Pravastatin, Rosuvastatin, or Simvastatin)
REZDIFFRA increased plasma concentrations of some statins (atorvastatin,

Clinical Impact

pravastatin, rosuvastatin and simvastatin) [see Clinical Pharmacology(12.3)], which may increase the risk of adverse reactions related to thesedrugs.
6

Reference ID: 5346680

Intervention
CYP2C8 Substrates

Rosuvastatin and simvastatin: Limit daily statin dosage to 20 mg.
Pravastatin and atorvastatin: Limit daily statin dosage to 40 mg.

Resmetirom is a weak CYP2C8 inhibitor. Resmetirom increases exposure
Clinical Impact of CYP2C8 substrates [see Clinical Pharmacology (12.3)], which may
increase the risk of adverse reactions related to these substrates.
Monitor patients more frequently for substrate-related adverse reactions if
Intervention REZDIFFRA is co-administered with CYP2C8 substrates where minimal
concentration changes may lead to serious adverse reactions.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on REZDIFFRA use in pregnant women to evaluate for a drugassociated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
There are risks to the mother and fetus related to underlying NASH with liver fibrosis (see Clinical
Considerations). In animal reproduction studies, adverse effects on embryo-fetal development
occurred in pregnant rabbits treated with resmetirom at 3.5 times the maximum recommended dose
during organogenesis. These effects were associated with maternal toxicity, whereas no embryo-fetal
effects were observed at lower dose levels with better tolerance in pregnant rabbits. No embryo-fetal
developmental effects occurred in pregnant rats treated with resmetirom or the metabolite MGL-3623.
A pre- and postnatal development study in rats with maternal dosing of resmetirom duringorganogenesis through lactation showed a decrease in birthweight and increased incidence ofstillbirths and mortality (postnatal days 1-4) at 37 times the maximum recommended dose (see Data).
These effects were associated with marked suppression of maternal T4, T3, and TSH levels.
The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, and other adverse outcomes. In the U.S.
general population, the estimated background risk of major birth defects and miscarriage in clinicallyrecognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Report pregnancies to Madrigal Pharmaceuticals, Adverse Event reporting line at 1-800-905-0324
and https://www.madrigalpharma.com/contact/.
Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
There are risks to the mother and fetus related to underlying maternal NASH with liver fibrosis, suchas increased risks of gestational diabetes, hypertensive complications, preterm birth, and postpartum
hemorrhage.
Data
Animal Data
No effects on embryo-fetal development were observed in pregnant rats treated orally with up to 100
mg/kg/day (21 times the maximum recommended dose based on AUC [area under the plasma
concentration-time curve]) or in pregnant rabbits treated orally with up to 30 mg/kg/day (2.8 times the
maximum recommended dose based on AUC) during the period of organogenesis. Oraladministration of 75 mg/kg/day in pregnant rabbits (3.5 times the maximum recommended dose
based on AUC) produced an increase in post-implantation loss and decreases in viable fetuses and7

Reference ID: 5346680

fetal weight. These effects were likely due to maternal toxicity (i.e., marked reductions in weight gain
and food consumption).
A pre- and postnatal development study was performed using oral administration of 3, 30, or 100
mg/kg/day in female rats during organogenesis through lactation. Treatment with 100 mg/kg/day (37times the maximum recommended dose based on AUC) produced increases in number of stillborn,
pup deaths during postnatal days 1-4, and pups with absence of milk in stomach. Birthweight was
decreased by 10% in this dose group, with recovery to normal body weight thereafter. The effects inoffspring were associated with marked reductions in maternal plasma levels of T4 (88% decrease),
T3 (79% decrease), and TSH (44% decrease). No effects on postnatal development were observedat doses up to 30 mg/kg/day (7.2 times the maximum recommended dose based on AUC). This study
lacked a complete evaluation of physical and neurobehavioral development in offspring; however, noeffects of resmetirom were noted in tests of learning and memory.
The metabolite MGL-3623 was tested for its effects on embryo-fetal development. No effects wereobserved in pregnant rats treated orally with up to 100 mg/kg/day MGL-3623 (4.7 times the maximum
recommended dose based on AUC for MGL-3623) during the period of organogenesis.
8.2 Lactation
Risk Summary
There is no information regarding the presence of REZDIFFRA in human or animal milk, the effects
on the breast-fed infant, or the effects on milk production. The developmental and health benefits ofbreastfeeding should be considered along with the mother's clinical need for REZDIFFRA and any
potential adverse effects on the breastfed infant from REZDIFFRA or from the underlying maternal
condition.
8.4 Pediatric Use
The safety and effectiveness of REZDIFFRA have not been established in pediatric patients.
8.5 Geriatric Use
In Trial 1, of the 594 patients with NASH who received at least one dose of REZDIFFRA, 149 (25%)
were 65 years of age and older and 13 (2%) were 75 years of age and older [see Clinical Studies (14)].
No overall differences in effectiveness but numerically higher incidence of adverse reactions have been
observed in patients 65 years of age and older compared to younger adult patients.
8.6 Renal Impairment
The recommended dosage in patients with mild or moderate renal impairment is the same as in patientswith normal kidney function. REZDIFFRA has not been studied in patients with severe renal impairment[see Clinical Pharmacology (12.3)].
8.7 Hepatic Impairment
Avoid use of REZDIFFRA in patients with decompensated cirrhosis (consistent with moderate tosevere hepatic impairment). Moderate or severe hepatic impairment (Child-Pugh Class B or C)
increases resmetirom Cmax and AUC [see Clinical Pharmacology (12.3)], which may increase the riskof adverse reactions.
No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh ClassA) [see Clinical Pharmacology (12.3)].
The safety and effectiveness of REZDIFFRA have not been established in patients with NASH
cirrhosis.
8

Reference ID: 5346680

11 DESCRIPTIONREZDIFFRA (resmetirom) tablets contain resmetirom, a thyroid hormone receptor-beta agonist. The
chemical name for REZDIFFRA is 2-[3,5-Dichloro-4-((6-oxo-5-(propan-2-yl)-1,6-dihydropyridazin-3yl)oxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile. The molecular formula is
C17H12Cl2N6O4 and the molecular weight is 435.22. The chemical structure is:

Resmetirom has low aqueous solubility below pH 6 and higher solubility above pH 7 (0.44 mg/mL at
pH 7.04).
REZDIFFRA tablets are supplied in 60 mg, 80 mg, and 100 mg strengths for oral administration. Eachtablet contains the active ingredient, resmetirom, and the following USP/NF excipients: colloidal
silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose.
REZDIFFRA tablets are film-coated with an Opadry coating comprised of polyethylene glycol,
polyvinyl alcohol, talc, titanium dioxide, red iron oxide (100 mg tablets), yellow iron oxide (80 mg and
100 mg tablets).
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β). Resmetirom produced
83.8% of the maximum response compared to triiodothyronine (T3), with an EC50 of 0.21 µM in an invitro functional assay for THR-β activation. The same functional assay for thyroid hormone receptoralpha (THR-α) agonism showed 48.6% efficacy for resmetirom relative to T3, with an EC50 of 3.74
µM. THR-β is the major form of THR in the liver, and stimulation of THR-β in the liver reduces
intrahepatic triglycerides, whereas actions of thyroid hormone outside the liver, including in heart andbone, are largely mediated through THR-α.
12.2 Pharmacodynamics
Liver Fat Content
Resmetirom decreases liver fat content as measured by magnetic resonance imaging-protein density
fat fraction (MRI-PDFF) or FibroScan controlled attenuation parameter (CAP).
Reductions in liver fat content by MRI-PDFF were observed at 16 (the first assessment) and 52 weeks
of treatment. Reductions in liver fat content by CAP were observed at 52 weeks of treatment.
Prohormone FT4Resmetirom decreased concentrations of prohormone FT4 were observed at the first assessment at
4 weeks of treatment. Similar decreases in FT4 were observed during the treatment [see Adverse
Reactions (6.1)].
Sex Hormone Binding Globulin (SHBG)
9

Reference ID: 5346680

Resmetirom increased concentrations of sex hormone binding globulin (SHBG) were observed at thefirst assessment at 4 weeks of treatment, and at longer durations of treatment. The clinicalsignificance of this change is unknown.
Cardiac Electrophysiology
At a dose two times the maximum recommended dose, REZDIFFRA does not prolong the QT interval
to any clinically relevant extent.
12.3 Pharmacokinetics
Following once daily doses, steady state is typically reached within 3 to 6 days of dosing. Resmetirom
steady state exposure increases in a dose proportional manner between doses of 40 mg (0.5 times
the lowest approved recommended dose) and 100 mg. Resmetirom exposure increases in a greaterthan dose proportional manner between doses of 100 mg and 200 mg (2 times the highest approved
recommended dose) by about 5.6-fold. Resmetirom exposure increased 1.5- to 3-fold following once
daily dosing; however, the MGL-3623 metabolite does not accumulate. The estimated resmetirom
systemic exposure at steady state in NASH patients is summarized in Table 5. Resmetirom exposure
is similar between NASH patients with F2 stage fibrosis and F3 stage fibrosis.
Table 5: Resmetirom Estimated Systemic Exposure at Steady State in Patients with NASH with
Fibrosis (F2 and F3)ParameterCmax,ss (ng/mL)a
AUCtau,ss (ng*h/mL)a

Resmetirom 80 mg
Once Daily
Mean (CV%)
778 (41.5)

Resmetirom 100 mg
Once Daily
Mean (CV%)
971 (40.9)

5850 (60.5)7780 (65.5)

Abbreviations: AUCtau,ss = area under the concentration-versus-time curve over one dosing interval at steady state; Cmax,ss= maximum concentration at steady state; CV = arithmetic coefficient of variation

Absorption
The resmetirom median time to maximum plasma concentration (Tmax) is approximately 4 hours
following multiple daily doses of resmetirom 80 mg or 100 mg.
Effect of Food
No clinically significant differences in resmetirom pharmacokinetics were observed following
administration with a high-fat meal (approximately 150, 250, and 500-600 calories from protein,carbohydrate, and fat, respectively). Concomitant food administration resulted in a 33% decrease inCmax, an 11% decrease in AUC, and a delay in median Tmax by about 2 hours compared to underfasted condition.
Distribution
Resmetirom apparent volume of distribution (Vd/F) at steady-state is 68 (227%) L. Resmetirom isgreater than 99% protein-bound.
Elimination
Resmetirom median terminal plasma half-life (t½) is 4.5 hours and the steady state apparent
clearance (CL/F) is 17.5 (56.3%) L/h.

10

Reference ID: 5346680

Metabolism
Resmetirom is metabolized by CYP2C8 and is not metabolized by other CYP enzymes in vitro.
MGL-3623 is a major metabolite with a 28-times lower potency for THR-β than resmetirom.
MGL-3623 represents 33% to 51% of resmetirom AUC at steady state following administration of 100
mg once daily.
Excretion
Following oral administration of a 100 mg radio-labeled dose of resmetirom, approximately 67% of thetotal radioactive dose was recovered in the feces, mostly as metabolites and 24% of the total
radioactive dose was recovered in the urine. Unchanged labeled resmetirom was not detected infeces and accounted for 1% of the dose recovered in urine. A metabolite MGL-3623 accounted for
3.3% and 16% of the dose recovered in feces and urine, respectively. Oxalic acid metabolite wasobserved in plasma but not in urine.
Specific Populations
No clinically significant differences in the pharmacokinetics of resmetirom were observed based onage (18 to 83 years), sex, race (White, Black, or Asian), or ABCG2 genotype (BCRP p.Gln141Lys,
p.Val12Met).
Population PK analyses indicated no clinically significant difference in the pharmacokinetics ofresmetirom by mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m2, Modification ofDiet in Renal Disease (MDRD)). The effect of severe renal impairment (eGFR < 30 mL/min/1.73 m2,
MDRD) on resmetirom pharmacokinetics is unknown.
Body Weight
A clinically significant difference in resmetirom exposure was not observed with the recommended
weight-based dosage. However, resmetirom CL/F and Vd/F increase with increasing body weight,
resulting in lower resmetirom exposure in patients with higher body weight receiving the same dosage
as lower weight patients [see Dosage and Administration (2.1)].
Patients with Hepatic Impairment
Patients with Hepatic Impairment: Following repeated 80 mg once daily dosing of REZDIFFRA for 6days, resmetirom AUC was 1.3-fold, 2.7-fold and 19-fold higher in patients with mild, moderate andsevere hepatic impairment (Child-Pugh A, B and C), respectively compared to subjects with normal
hepatic function. Resmetirom Cmax was 1.2-fold, 1.7-fold and 8.1-fold higher in patients with mild,moderate and severe hepatic impairment, respectively, compared to subjects with normal hepaticfunction (Table 6).
In the same study, MGL-3623 AUCtau was 1.3-fold, 2-fold and 5.8-fold higher in patients with mild,moderate and severe hepatic impairment, respectively, compared to subjects with normal hepaticfunction [see Use in Specific Populations (8.7)].
Table 6: Mean (CV%) Resmetirom Systemic Exposure in Subjects with Normal Hepatic
Function and Non-NASH Patients with Hepatic Impairment Following REZDIFFRA 80 mg Once
Daily for 6 Days and Exposure Change Relative to Normal Hepatic Function
Parameter

NormalHepatic
Function(N = 7)

Child-Pugh Class
A
B
C
Mild
Moderate
Severe(N = 10)(N = 9)(N = 3)
Resmetirom
11

Reference ID: 5346680

Cmax,ss (ng/mL)a
AUCtau,ss (ng*h/mL)a1070 (51.0)
5100 (51.5)

a Exposure parameters presented as Mean (CV%)

1390 (67.8)
5570 (66.4)

1830 (47.5)
15100 (65.8)b7730 (17.4)
97600 (39.0)

b N = 8Abbreviations: AUCtau,ss = area under the concentration-versus-time curve over one dosing interval at steady state; Cmax,ss= maximum concentration at steady state; CV = arithmetic coefficient of variation

NASH Patients with Mild Hepatic Impairment (Child-Pugh A): Geometric mean AUC and Cmax in
NASH cirrhosis patients with mild hepatic impairment (Child-Pugh Class A; n = 20) were 6% higher
and 10% lower, respectively, compared to non-cirrhotic NASH patients following repeated 100 mg
once daily dosing of REZDIFFRA for 6 days. The safety and effectiveness of REZDIFFRA have notbeen established in patients with NASH cirrhosis.
Drug Interaction Studies
Clinical Studies
Moderate CYP2C8 Inhibitors: Resmetirom Cmax increased 1.3-fold and AUC 1.7-fold following
concomitant use of multiple doses of REZDIFFRA 100 mg/day with clopidogrel (a moderate CYP2C8
inhibitor) at steady-state in healthy subjects [see Drug Interactions (7.1)].
CYP2C8 Substrates: Pioglitazone (a CYP2C8 substrate) Cmax was unchanged and AUC increased
1.5-fold following concomitant use of a single oral dose of pioglitazone (15 mg) with resmetirom atsteady state (100 mg/day) in healthy subjects [see Drug Interactions (7.1)].
Simvastatin: Simvastatin (OATP1B1 and OATP1B3 substrate) Cmax increased 1.4-fold and AUC 1.7fold following concomitant use of a single oral dose of simvastatin (20 mg) with resmetirom at steadystate (100 mg/day) in healthy subjects [see Drug Interactions (7.2)].
Rosuvastatin: Rosuvastatin (BCRP, OATP1B1, and OATP1B3 substrate) Cmax increased 2.9-fold and
AUC 1.8-fold following concomitant use of a single oral dose of rosuvastatin (10 mg) with resmetirom
at steady state (at two times the highest recommended dosage) in healthy subjects [see Drug
Interactions (7.2)].
Pravastatin: Pravastatin (OATP1B1 and OATP1B3 substrate) Cmax increased 1.3-fold and AUC 1.4fold following concomitant use of a single oral dose of pravastatin (40 mg) with resmetirom at steadystate (100 mg/day) in healthy subjects [see Drug Interactions (7.2)].
Atorvastatin: Atorvastatin (BCRP, OATP1B1, and OATP1B3 substrate) Cmax was unchanged and
AUC increased 1.4-fold following concomitant use of a single oral dose of atorvastatin (20 mg) withresmetirom at steady state (100 mg/day) in healthy subjects. Atorvastatin lactone Cmax increased 2.0fold and AUC increased 1.8-fold [see Drug Interactions (7.2)].
Other Drugs: No clinically significant differences in the pharmacokinetics of R-warfarin or S-warfarin
were observed when used concomitantly with resmetirom.
In Vitro Studies
CYP450 Enzymes: Resmetirom is an inhibitor of CYP2C8.
Glucuronidation Enzymes: Resmetirom is an inhibitor of UDP-glucuronosyltransferases (UGTs) 1A4
and 1A9. The clinical relevance of UGT1A4 and UGT1A9 inhibition is unknown.
Transporters: Resmetirom is a substrate for organic anion-transporting polypeptides (OATP) 1B1 and
1B3 and breast cancer resistance protein (BCRP). Resmetirom inhibits OATP1B1, OATP1B3, BCRP,
12Reference ID: 5346680

OAT3, and bile salt export pump (BSEP). The clinical significance of OAT3 and BSEP inhibition is
unknown.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
In a 2-year study in CD-1 mice, resmetirom produced leiomyoma or leiomyosarcoma in the uterus at
a dose of 100 mg/kg/day (51 times the maximum recommended dose based on AUC). No
tumorigenic effects were observed in female mice at doses of up to 30 mg/kg/day (14 times the
maximum recommended dose based on AUC) or in male mice at doses of up to 100 mg/kg/day (35times the maximum recommended dose based on AUC).
In a 2-year study in Sprague-Dawley rats, resmetirom produced benign fibroadenoma in the
mammary gland of males at a dose of 30 mg/kg/day (6.5 times the maximum recommended dose
based on AUC). No tumorigenic effects were observed in male rats at doses of up to 6 mg/kg/day(3.7 times the maximum recommended dose based on AUC) or in female rats at doses of up to 30
mg/kg/day (3.4 times the maximum recommended dose based on AUC).
In a 26-week study in transgenic [CByB6F1-Tg(HRAS)2Jic] mice, the major metabolite of resmetirom,
MGL-3623, was not tumorigenic at doses of up to 1500 mg/kg/day.
Mutagenesis
Resmetirom was negative in the in vitro bacterial reverse mutation (Ames) assay, the in vitro
chromosomal aberration assay in human peripheral blood lymphocytes, the in vitro micronucleus
assay in L5178Y tk+/- mouse lymphoma cells, and the in vivo rat micronucleus assay.
The metabolite MGL-3623 was negative in the in vitro bacterial reverse mutation (Ames) assay andthe in vivo rat micronucleus assay. MGL-3623 tested positive in the presence of metabolic activationin the in vitro micronucleus assay with TK6 human lymphoblast cells, with the increase in micronuclei
limited to a single concentration that produced 59% growth inhibition.
Impairment of Fertility
Resmetirom had no effects on fertility or reproductive function in male and female rats at oral dosesof up to 30 mg/kg/day (6.9 times and 2.6 times the maximum recommended dose in male and female
rats, respectively, based on AUC).
14 CLINICAL STUDIESThe efficacy of REZDIFFRA was evaluated based on an efficacy analysis at Month 12 in Trial 1(NCT03900429), a 54-month, randomized, double-blind, placebo-controlled trial. Enrolled patients
had metabolic risk factors and a baseline or recent liver biopsy showing NASH with fibrosis stage 2 or
3 and a NAFLD Activity Score (NAS) of at least 4. Efficacy determination was based on the effect of
REZDIFFRA on resolution of steatohepatitis without worsening of fibrosis and one stage improvement
in fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 12 months.
The month 12 analysis included 888 F2 and F3 (at eligibility) patients randomized 1:1:1 to receive
placebo (n = 294), REZDIFFRA 80 mg once daily (n = 298), or REZDIFFRA 100 mg once daily (n =296), in addition to lifestyle counseling on nutrition and exercise. Patients were on stable doses of
medications for diabetes, dyslipidemia, and hypertension.
13

Reference ID: 5346680

Demographic and baseline characteristics were balanced between treatment and placebo groups.
Overall, the median (Q1 to Q3) age of patients at baseline was 58 (51 to 65) years, 56% were female,
21% were Hispanic, 89% were White, 3% were Asian, and 2% were Black or African American.
Median (Q1 to Q3) body mass index (BMI) was 35 (31 to 40) kg/m2 and median (Q1 to Q3) bodyweight was 99 (85 to 114) kg. Baseline characteristics are presented in Table 7.
Table 7: Baseline Characteristics in Adults Patients with Noncirrhotic NASH with Stage 2 toStage 3 Fibrosis in Trial 1abCharacteristic
Fibrosis stage, n (%)
F2F3Type 2 Diabetes, n (%)
Hypertension, n (%)
Dyslipidemia, n (%)
Statin use, n (%)
Thyroxine use, n (%)
Vibration-controlled Transient Elastography (VCTE) (kPa), Median(Q1, Q3)a, b
Controlled attenuation parameter (CAP) (Db/M), Median (Q1, Q3)aFibrosis Index Based on 4 Factors (FIB-4), Median (Q1, Q3)aEnhanced Liver Fibrosis (ELF), Median (Q1, Q3)aLess than 5% missingness in these variables is omitted.
kPa = kilopascal; Db/M = decibels per meter

Overall
N=888
328 (37)560 (63)608 (68)700 (79)633 (71)434 (49)
124 (14)12 (10, 15)349 (320, 378)
1.3 (1, 1.8)
9.7 (9.2, 10.4)

Table 8 presents the Month 12 histopathology results comparing REZDIFFRA with placebo on 1) thepercentage of patients with resolution of steatohepatitis and no worsening of liver fibrosis and 2) thepercentage of patients with at least one stage improvement in liver fibrosis and no worsening ofsteatohepatitis. Two pathologists, Pathologist A and Pathologist B, independently read the liverbiopsies for each patient. Both the 80 mg once daily and the 100 mg once daily dosages of
REZDIFFRA demonstrated improvement on these histopathology endpoints at Month 12 compared toplacebo. In a statistical analysis incorporating both pathologists’ independent readings, REZDIFFRA
achieved statistical significance on both histopathology endpoints for both doses.
Examination of age, gender, diabetes status (Yes or No), and fibrosis stage (F2 or F3) subgroups did
not identify differences in response to REZDIFFRA among these subgroups. The majority of patientsin the trial were white (89%); there were too few patients of other races to adequately assess
differences in response by race.

14

Reference ID: 5346680

Table 8: Efficacy Results at Month 12 in Adult Patients with Noncirrhotic NASH with Stage 2 orStage 3 Fibrosis in Trial 1
REZDIFFRA
80 mg
Once Daily
Placebo
N=294
N=298
Resolution of steatohepatitis and no worsening of liver fibrosis
Response rate, Pathologist A (%)
13
27
Difference in response rate vs. placebo
14 (8, 20)(95% CI)
Response rate, Pathologist B (%)
926
Difference in response rate vs. placebo
17 (11, 23)(95% CI)
Improvement in liver fibrosis and no worsening of steatohepatitis
Response rate, Pathologist A (%)
15
23
Difference in response rate vs. placebo
8 (2, 14)(95% CI)
Response rate, Pathologist B (%)
13
23
Difference in response rate vs. placebo
11 (5, 17)(95% CI)

REZDIFFRA
100 mgOnce Daily
N=29636
23 (16, 30)
24
15 (9, 21)28
13 (7, 20)24
11 (5, 17)

Liver fibrosis was evaluated on the NASH Clinical Research Network (CRN) fibrosis score as 0 to 4. Resolution ofsteatohepatitis was defined as a score of 0–1 for inflammation, 0 for ballooning, and any value for steatosis. No worseningof steatohepatitis was defined as no increase in score for ballooning, inflammation, or steatosis. Estimated using the
Mantel-Haenszel method stratified by baseline type 2 diabetes status (presence or absence) and fibrosis stage (F2 or F3).
95% stratified Newcombe confidence intervals (CIs) are provided. Patients with missing liver biopsy at Month 12 areconsidered a non-responder.

Starting at Month 3 and through Month 12, there was a trend of greater reductions from baseline inaverage ALT and AST in the REZDIFFRA groups as compared to the placebo group.
16 HOW SUPPLIED/STORAGE AND HANDLINGHow Supplied

REZDIFFRA (resmetirom) tablets are packaged in white high-density polyethylene bottles closed witha child-resistant closure containing an induction seal.
60 mg Tablets: white oval-shaped film-coated tablets, debossed “P60” on one side and plain on theother side.
•

NDC 82576-060-30 60 mg tablets (30 count)

80 mg Tablets: yellow, oval-shaped, film-coated tablets, debossed with “P80” on one side and plainon the other side.
••

Bottle of 30 count (NDC 82576-080-30)
Bottle of 90 count (NDC 82576-080-90)

100 mg Tablets: beige to pink, oval-shaped, film-coated tablets, debossed with “P100” on one sideand plain on the other side.
•

Bottle of 30 count (NDC 82576-100-30)
15Reference ID: 5346680

•Bottle of 90 count (NDC 82576-100-90)

Storage and HandlingStore at 20 °C to 25°C (68 °F to 77°F); excursions permitted to 15 °C to 30°C (59° F to 86°F) [seeUSP Controlled Room Temperature].
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hepatotoxicity
Inform patients of the risk of hepatotoxicity. Instruct patients to immediately report any signs or
symptoms of severe liver injury (e.g., fatigue, nausea, vomiting, right upper quadrant pain or
tenderness, jaundice, fever, rash) to their healthcare provider [see Warnings and Precautions (5.1)].
Gallbladder-Related Adverse Reactions
Inform patients of the potential risk for cholelithiasis, cholecystitis, and obstructive pancreatitis(gallstones) during treatment with REZDIFFRA. Instruct patients to contact their healthcare provider ifthey develop signs or symptoms of these conditions [see Warnings and Precautions (5.2)].
Drug Interaction with Statins
Inform patients that concomitant use of REZDIFFRA with some statins may increase the risk of statinrelated adverse reactions (e.g., elevation of liver tests, myopathy, rhabdomyolysis) [see Warnings
and Precautions (5.3), Drug Interactions (7.2)].
Manufactured by: UPM Pharmaceuticals (Bristol, TN)
Manufactured for: Madrigal Pharmaceuticals, West Conshohocken, PA
REZDIFFRA™ (resmetirom) © 2024 Madrigal Pharmaceuticals, Inc.

Part number/Date

16

Reference ID: 5346680

PATIENT INFORMATIONREZDIFFRA (rez di' frah)(resmetirom)
tablets, for oral use

What is REZDIFFRA?
REZDIFFRA is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis(NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
It is not known if REZDIFFRA is safe and effective in children (under 18 years old).
Before you take REZDIFFRA, tell your healthcare provider about all of your medical conditions, including if
you:
•
•
•
•

have any liver problems other than NASH.
have gallbladder problems or have been told you have gallbladder problems, including gallstones.
are pregnant or plan to become pregnant. It is not known if REZDIFFRA will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if REZDIFFRA passes into your breast milk. Talk to yourhealthcare provider about the best way to feed your baby if you take REZDIFFRA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements.
REZDIFFRA and other medicines may affect each other, causing side effects. REZDIFFRA may affect the way othermedicines work, and other medicines may affect how REZDIFFRA works.
Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or
cyclosporine to suppress your immune system, because REZDIFFRA is not recommended in patients taking these
medicines.
Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines tohelp lower your cholesterol.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a
new medicine.
How should I take REZDIFFRA?
• Take REZDIFFRA exactly as your healthcare provider tells you to take it.
• Your dose of REZDIFFRA is based on your body weight.
• Take REZDIFFRA by mouth, 1 time a day with or without food.
What are the possible side effects of REZDIFFRA?
REZDIFFRA may cause serious side effects, including:• liver injury (hepatotoxicity). Stop taking REZDIFFRA and call your healthcare provider right away if you develop
the following signs or symptoms of hepatotoxicity:o tiredness
o fevero pain or tenderness in the uppero nauseao rashmiddle or upper right area ofo vomitingo your skin or the white part of your
your stomach (abdomen)eyes turns yellow (jaundice)•gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or
inflammation of the pancreas from gallstones can occur with NASH and may occur if you take REZDIFFRA. Call
your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea,
vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt
going from your abdomen to your back and the pain may happen with or without vomiting.

The most common side effects of REZDIFFRA include:• diarrhea• itching• nausea• stomach (abdominal) pain••

vomitingdizziness•

constipation

These are not all the possible side effects of REZDIFFRA. For more information, ask your healthcare provider or
pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to www.fda.gov/medwatch.
How should I store REZDIFFRA?
• Store REZDIFFRA at room temperature between 68ºF to 77ºF (20ºC to 25ºC).
Keep REZDIFFRA and all medicines out of the reach of children.

Reference ID: 5346680

General information about the safe and effective use of REZDIFFRA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use
REZDIFFRA for a condition for which it was not prescribed. Do not give REZDIFFRA to other people, even if they havethe same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about REZDIFFRA that is written for healthprofessionals.
What are the ingredients in REZDIFFRA?
Active ingredient: resmetirom
Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, andmicrocrystalline cellulose. The film coating contains: polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, rediron oxide (100 mg tablets), and yellow iron oxide (80 mg and 100 mg tablets).
Manufactured for and Distributed by:Madrigal Pharmaceuticals, Inc.
West Conshohocken, PA
This Patient Information has been approved by the U.S. Food and Drug Administration.

Reference ID: 5346680

Approved: 3/2024